Drug Markets/EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

1 NDCs across 1 manufacturers|0 Generic,1 Brand

Total NDCs

0G / 1B

Manufacturers

competing in market

Price Spread

$130.52 – $130.52

7d Activity

1 flat

of 1 total NDCs

Monthly average NADAC price per unit, split by generic and brand

1 manufacturer producing EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

1 NDCs total, 1 shown

Drug ↕	NDC	Manufacturer ↕	Price	Market Outlier	Class	7d Change ↕	Therapeutic Class
COMPLERA TABLET	61958110101	Gilead Sciences, Inc.	$130.5185 per EA	—	Brand	—	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor